Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
-
Patent number: 11678683Abstract: The invention related to a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation. The invention further relates to a method for producing a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation, to a method for preventing spoilage of a processed edible product, and to a method of preventing, reducing and/or eliminating the presence of fungi, bacteria and/or viruses on a processed edible product. The invention additionally relates to a use of a complex of a antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation for preventing, reducing and/or eliminating the presence of fungi, bacteria and/or viruses on a processed edible product.Type: GrantFiled: October 16, 2019Date of Patent: June 20, 2023Assignee: Ceradis B.V.Inventors: Jacobus Stark, Wilhelmus Maria van der Krieken, Christiaan Gerardus Johannes Maria Jans
-
Patent number: 11622939Abstract: An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.Type: GrantFiled: November 23, 2018Date of Patent: April 11, 2023Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Li Ding, Jun Dai, Chunrong Feng, Changliang Dai
-
Patent number: 11236059Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.Type: GrantFiled: August 8, 2018Date of Patent: February 1, 2022Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Philipp Klahn, Mark Broenstrup, Verena Fetz, Wera Collisi, Katrin I Mohr, Stephan Huettel, Werner Tegge
-
Patent number: 11166937Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.Type: GrantFiled: June 18, 2018Date of Patent: November 9, 2021Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
-
Patent number: 11155529Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.Type: GrantFiled: March 31, 2017Date of Patent: October 26, 2021Assignee: SHIELD TX (UK) LIMITEDInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
-
Patent number: 11142520Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.Type: GrantFiled: May 16, 2018Date of Patent: October 12, 2021Assignee: ARCTIC PHARMA ASInventors: Jo Klaveness, Bora Sieng, Steffi Lundvall, Claudia Alejandra Bøen, Kathrin Hnida
-
Patent number: 11104955Abstract: The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.Type: GrantFiled: December 29, 2017Date of Patent: August 31, 2021Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Arin K. Greene, Matthew Warman, Yue Huang
-
Patent number: 11066381Abstract: A urolithin-containing aqueous solution containing urolithin and collagen, a dried solid composition thereof, methods for producing these, and a stabilization method for urolithin.Type: GrantFiled: February 1, 2017Date of Patent: July 20, 2021Assignee: DAICEL CORPORATIONInventor: Takanori Nakajima
-
Patent number: 11020373Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.Type: GrantFiled: June 27, 2013Date of Patent: June 1, 2021Assignee: Amazentis SAInventors: Christopher Lawrence Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
-
Patent number: 10918111Abstract: The present invention provides an antimicrobial composition for coating surfaces that enables a reduction of up to one hundred percent of the microbial activity on any type of frequently used substrate or surface, comprising a compound of micronized high-purity metallic copper particles. Moreover, a process for preparing the composition is provided.Type: GrantFiled: December 29, 2016Date of Patent: February 16, 2021Assignee: ATACANALABInventors: Marisol Gómez Álvarez, Claudio Guillermo Ramírez Mora
-
Patent number: 10912756Abstract: Pharmaceutical composition comprising an aqueous solution of a taxane and an aqueous solution of a hydrophobic statin intended for use in treatment or prevention of human melanoma.Type: GrantFiled: January 19, 2018Date of Patent: February 9, 2021Assignee: UNIWERSYTET JAGIELLONSKIInventors: Wojciech Placha, Jacek Zagajewski, Małgorzata Szczygieł, Monika Piwowar
-
Patent number: 10889574Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: August 30, 2019Date of Patent: January 12, 2021Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10785978Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I) wherein R is —OH, ?O, —OC(O)R4, —OR6, or —(OR6)2, wherein each R6 is independently an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated, hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O: each Z is independently (CH) or (CH2); y is a numeral selected from 1 and 2; R1 is H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is H, a branched or straight chain, saturated or unsaturated hydrocarbyl groType: GrantFiled: January 24, 2018Date of Patent: September 29, 2020Assignee: Bedoukian Research, Inc.Inventor: Robert H. Bedoukian
-
Patent number: 10688109Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 26, 2018Date of Patent: June 23, 2020Assignee: Vanderbilt UniversityInventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
-
Patent number: 10640496Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: June 15, 2017Date of Patent: May 5, 2020Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10610489Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.Type: GrantFiled: September 30, 2010Date of Patent: April 7, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Peter Schneider, Wolfram Eisenreich, Nantharat Pearnchob
-
Patent number: 10555930Abstract: This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containing the complex, and their uses in the manufacture of a medicament for treating diabetes and/or diabetes-related diseases.Type: GrantFiled: November 28, 2016Date of Patent: February 11, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Pengcho Tang, Zheng Gu, Wuyong Wu, Zongyuan Zhang, Panpan Kang, Tong Qu
-
Patent number: 10398653Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.Type: GrantFiled: January 29, 2019Date of Patent: September 3, 2019Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kenta Wada, Tomoaki Hirayama, Kenichi Sakai, Shiho Yoshimura
-
Patent number: 10383949Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.Type: GrantFiled: June 11, 2018Date of Patent: August 20, 2019Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
-
Patent number: 10351590Abstract: Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.Type: GrantFiled: November 25, 2014Date of Patent: July 16, 2019Assignees: Imstar Therapeutics Inc., Universite LavalInventors: Anthony A. Shaw, Jean-Pierre Julien, Agnes H. Chan
-
Patent number: 10307419Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.Type: GrantFiled: September 22, 2017Date of Patent: June 4, 2019Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventor: Yoshiharu Inoue
-
Patent number: 10231930Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.Type: GrantFiled: December 26, 2014Date of Patent: March 19, 2019Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kenta Wada, Tomoaki Hirayama, Kenichi Sakai, Shiho Yoshimura
-
Patent number: 10179157Abstract: The present invention discloses a slim and aqueous extract of Garcinia cambogia comprising (?)-hydroxycitric acid as dietary product for weight management. The present invention also discloses a process of preparation of aqueous extract wherein the Garcinia cambogia fruit rinds are subjected to cold circulation to retain the phytochemical components and the aqueous extract is adjusted to neutral pH and stabilized with triple mineral salt of calcium, magnesium and potassium and decolorized using activated carbon. The colorless, odorless aqueous extract obtained is subjected to qualitative and quantitative analysis to obtain pure concentrate, which is useful in food, beverage and pharmaceutical industries as dietary supplement. The concentrate equivalent to 1500 mg of (?)-hydroxycitric acid on dried basis is used for the consumption with the distilled water. The slim and aqueous extract concentrate of Garcinia cambogia is useful in treatment of overweight, obesity and hypercholesterolemia.Type: GrantFiled: February 15, 2016Date of Patent: January 15, 2019Inventors: Venkatachalam Hariharan, PradeepKumar Siddavvanahalli Virupakshappa, Kanchana Hariharan, Vinayaka Neechadi Puppadar, Paranjothi Kanni
-
Patent number: 10149830Abstract: The instant disclosure is related to lactone-containing compounds of formula (I), compositions thereof, and use thereof for treating proliferative disease or disorders. Also provided herein are methods of making, identifying, or characterizing the compounds, or compositions thereof.Type: GrantFiled: May 26, 2017Date of Patent: December 11, 2018Assignee: Cushing AcademyInventor: William R. Sponholtz, III
-
Patent number: 10040776Abstract: A compound of formula (I) is provided wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavoring composition, or as a masking agent for odors and/or flavors.Type: GrantFiled: March 2, 2017Date of Patent: August 7, 2018Assignee: V. MANE FILSInventors: Jean Mane, Caroline Plessis, Jean-Jacques Chanot
-
Patent number: 9914969Abstract: The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects.Type: GrantFiled: January 28, 2013Date of Patent: March 13, 2018Assignee: CORNELL UNIVERSITYInventors: James Thomas Brenna, Holly Turner Reardon, Sesha Durga Kumar Kothapalli
-
Patent number: 9750759Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.Type: GrantFiled: August 12, 2015Date of Patent: September 5, 2017Assignee: Pharma Mar, S.A.Inventors: Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
-
Patent number: 9630764Abstract: An oxygen-absorbing resin composition copolymerized polyolefin compound including a copolymerized polyolefin compound and a transition metal catalyst, wherein the copolymerized polyolefin compound is a copolymerized polyolefin compound including at least one of constitutional unit (a) selected from the group consisting of the constitutional units represented by the general formula (1), and at least one of the constitutional unit (b) having an indane ring, selected from the group consisting of the constitutional units represented by the general formulas (2) and (3).Type: GrantFiled: July 9, 2013Date of Patent: April 25, 2017Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Shinpei Iwamoto, Satoshi Okada, Shinichi Ikeda
-
Patent number: 9540307Abstract: The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease.Type: GrantFiled: May 7, 2015Date of Patent: January 10, 2017Assignee: JIVA PHARMA, INC.Inventor: Om P Goel
-
Patent number: 9434684Abstract: To provide a novel pesticide, especially a fungicide and a nematocide.Type: GrantFiled: July 12, 2013Date of Patent: September 6, 2016Assignee: Nissan Chemical Industries, Ltd.Inventors: Motoyoshi Iwasa, Keisuke Tsuji, Mitsutaka Tomizawa, Takeshi Mita, Hidehito Kuwahara, Miho Asahi, Hotaka Imanaka
-
Patent number: 9345671Abstract: The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.Type: GrantFiled: April 27, 2004Date of Patent: May 24, 2016Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiyuki Takagi, Iichiro Shimomura, Yuji Matsuzawa, Tohru Funahashi
-
Patent number: 9321777Abstract: The disclosure relates to compounds of formula (I): wherein , A, W, X, and Ra are as defined in the disclosure, and salts thereof, and to pharmaceutical compositions comprising said compounds, to processes for preparing them, and to their use as medicaments, in particular as MET inhibitors.Type: GrantFiled: June 4, 2015Date of Patent: April 26, 2016Assignee: SANOFIInventors: Eva Albert, Eric Bacque, Conception Nemecek, Antonio Ugolini, Sylvie Wentzler
-
Patent number: 9314029Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, saturated oType: GrantFiled: April 30, 2013Date of Patent: April 19, 2016Assignee: Bedoukain Research, Inc.Inventor: Robert H. Bedoukian
-
Patent number: 9307783Abstract: Homeopathic water compositions are described, as well as beverage articles for making drinking water formulations with such compositions. One such beverage article includes a water bottle, and a dispensing cap adapted to be secured to the water bottle. The dispensing cap contains dried homeopathic composition-coated sucrose or sucrose/starch particles that are dispensable into water in the water bottle by user actuation of the dispensing cap, to constitute the homeopathic water formulation for consumption.Type: GrantFiled: July 29, 2012Date of Patent: April 12, 2016Assignee: ESSENTIALIFE HOMEOPATHICSInventor: Ramin Stephan Bayani
-
Patent number: 9241914Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.Type: GrantFiled: February 20, 2015Date of Patent: January 26, 2016Assignee: Land O'Lakes, Inc.Inventor: Cindie M. Luhman
-
Patent number: 9089612Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.Type: GrantFiled: December 3, 2010Date of Patent: July 28, 2015Assignee: SYNERGY PHARMACEUTICALS, INC.Inventor: Kunwar Shailubhai
-
Publication number: 20150148347Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.Type: ApplicationFiled: November 25, 2014Publication date: May 28, 2015Inventors: Iain LINGARD, Dieter HAMPRECHT
-
Publication number: 20150148411Abstract: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.Type: ApplicationFiled: November 25, 2014Publication date: May 28, 2015Inventors: Daniel Schramek, Elaine Fuchs
-
Publication number: 20150148410Abstract: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.Type: ApplicationFiled: September 10, 2012Publication date: May 28, 2015Applicant: Texas Heart InstituteInventors: Chu-Huang Chen, Liang-Yin Ke
-
Patent number: 9034921Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: June 1, 2012Date of Patent: May 19, 2015Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
-
Publication number: 20150133540Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, saturType: ApplicationFiled: April 30, 2013Publication date: May 14, 2015Inventor: Robert H. Bedoukian
-
Patent number: 9029413Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.Type: GrantFiled: April 3, 2012Date of Patent: May 12, 2015Assignee: The Trustees of Princeton UniversityInventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20150119414Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.Type: ApplicationFiled: January 2, 2015Publication date: April 30, 2015Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
-
Publication number: 20150110871Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.Type: ApplicationFiled: January 3, 2015Publication date: April 23, 2015Inventor: David Wong
-
Publication number: 20150104504Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.Type: ApplicationFiled: May 7, 2013Publication date: April 16, 2015Inventors: Bernardus Machielse, Timothy J. Maines, Michael H. Davidson, Bharat M. Mehta
-
Patent number: 9006468Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: January 25, 2012Date of Patent: April 14, 2015Assignee: Dow AgroSciences, LLC.Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20150094323Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventor: Susanne Riel
-
Publication number: 20150094322Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventor: Susanne Riel
-
Publication number: 20150080463Abstract: Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.Type: ApplicationFiled: March 16, 2011Publication date: March 19, 2015Applicant: BG MEDICINE, INC.Inventor: Pieter Muntendam
-
Publication number: 20150065567Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis.Type: ApplicationFiled: August 15, 2014Publication date: March 5, 2015Applicant: Chiesi Farmaceutici S.p.A.Inventors: Bruno Imbimbo, Marina Pizzi, Daniel Chain